Increased expression of CYP17A1 indicates an effective targeting of the androgen receptor axis in castration resistant prostate cancer (CRPC)

Recent breakthrough therapies targeting androgen receptor signalling in castration resistant prostate cancer (CRPC) involve multifunctional androgen receptor (AR) blockade and exhaustive androgen deprivation. Nevertheless, limitations to an enduring effectiveness of new drugs are anticipated in resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bremmer, Felix, Jarry, Hubertus, Strauß, Arne, Behnes, Carl Ludwig, Trojan, Lutz, Thelen, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193971/
https://www.ncbi.nlm.nih.gov/pubmed/25332874
http://dx.doi.org/10.1186/2193-1801-3-574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4193971/
https://www.ncbi.nlm.nih.gov/pubmed/25332874
http://dx.doi.org/10.1186/2193-1801-3-574

Ejemplares similares